Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

Junshik Hong, Ji Yeon Kim, Hee Kyung Ahn, Sang Min Lee, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Jeong Yeal Ahn, Sanghui Park, Sang Pyo Lee, Dong Bok Shin, Jae Hoon Lee

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Purpose: The purpose of this study is to evaluate risk factors for infusion-related reaction (IRR) following rituximab administration in patients with B cell non-Hodgkin lymphoma. Methods: A retrospective analysis was conducted of patients with newly diagnosed B cell lymphoma who have received rituximab-included immunochemotherapy with appropriate premedication and commonly used schedule of infusion rate. IRRs were graded by review of the patients' electronic medical record according to the Common Terminology Criteria for Adverse Events version 4.0. Results: One hundred and sixty-nine patients were included in the analysis and most of the patients (150; 88.8 %) had diffuse large B cell lymphoma (DLBCL). Thirty-six patients (21.3 %) had any grade of IRRs: 23 patients were grade (G) 1 (13.6 %), 13 had ≥G2 IRRs (7.7 %), and only 4 had ≥G3 IRRs (2.4 %). All except one patient had IRR during the first cycle and only two had repetitive IRR thereafter. Bone marrow (BM) involvement was the strongest risk factor for IRR in multivariable analysis (odds ratio 4.06, 95 % confidence interval 1.67-9.89; p∈=∈0.002). A subgroup analysis confined to patients with DLBCL showed very similar results when compared with the entire population, and patients with DLBCL who had ≥G2 IRR showed shorter event-free and overall survival when compared to those who did not. Conclusions: BM involvement is predictive of occurrence of IRR during rituximab administration in patients with B cell lymphoma. More intensive premedication and careful observation for IRR during rituximab administration are required for patients with B cell lymphoma who have BM involvement.

Original languageEnglish
Pages (from-to)1145-1152
Number of pages8
JournalSupportive Care in Cancer
Volume21
Issue number4
DOIs
StatePublished - Apr 2013

Keywords

  • Bone marrow involvement
  • Infusion-related reaction
  • Non-Hodgkin lymphoma
  • Rituximab

Fingerprint

Dive into the research topics of 'Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma'. Together they form a unique fingerprint.

Cite this